Clinical trials: Schizophrenia Spectrum
Schizophrenia, Psychotic Disorders
CAFE Comparison of Atypicals in First Episode of Psychosis
The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day)…
- Conditions
- Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
- Trial name
- NCT00034892
- Testing
- Olanzapine, risperidone
- Where
- 26 sites in United States, Canada
- Sponsor
- AstraZeneca
Schizophrenia and Disorders With Psychotic Features
The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms
The purpose of this study is to investigate if minocycline limits the development of negative symptoms in early psychosis and to test via what mechanism of action this change occurs.
- Trial name
- BeneMin (NCT02928965)
- Testing
- Minocycline
- Volunteers
- 207 people
- Sponsor
- University of Manchester
Schizophrenia, Communication
The Two-Way Communication Checklist (2-COM) in First Episode Psychosis Patients in Hong Kong
The Two-Way Communication Checklist (2-COM) is a communication tool developed by van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and…
- Trial name
- NCT02435784
- Testing
- The Two-Way Communication Checklist, Treatment as usual
- Where
- Hong Kong
- Volunteers
- 84 people
- Sponsor
- The University of Hong Kong
Schizophrenia
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
- Trial name
- NCT01908192
- Testing
- NaBen®
- Where
- 23 sites in United States, Taiwan
- Volunteers
- 60 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Schizophrenia, Schizotypal Disorder
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
The OPUS YOUNG (OY) study investigates the efficacy of early intervention service versus treatment as usual (TAU) for adolescents aged 12-17 years with a first-episode psychosis.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
- Trial name
- OPUS-YOUNG (NCT04916626)
- Testing
- OPUS YOUNG, Treatment as Usual
- Where
- Denmark
- Volunteers
- 284 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Prodromal Schizophrenia
Effects of NAC on Symptoms of CHR Patients
Schizophrenia is a chronic debilitating psychotic disorder. Identifying persons with "clinical high-risk" (CHR) symptoms, which are like those of schizophrenia but less severe, and providing psychiatric care to these individuals…
- Trial name
- NCT05142735
- Testing
- N-Acetylcysteine
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- Centre for Addiction and Mental Health
Psychosis
CLinical Utility of Early Intervention Including the 5-Step Precision Medicine (5SPM) Method in First-episode Psychosis: The CLUMP Project
CLUMP is a project of translational research that intends to bridge the gap between what we already know about pharmacogenetics of antipsychotic drugs and what we still do to treat patients with first-episode psychosis (FEP).
- Trial name
- CLUMP (NCT06453174)
- Testing
- Adherence to the first prescribed antipsychotic medication
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Schizophrenia, Prodrome
Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis
Early intervention in psychosis might be associated with better outcomes. However, intervention in the pre-psychotic phase has been questioned as, using current criteria, only 20-50% of individuals classified as prodromal develop…
- Trial name
- NCT00396643
- Testing
- Omega 3 fatty acids
- Where
- Austria
- Volunteers
- 81 people
- Sponsor
- Medical University of Vienna
Schizophrenia
Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome
Background: The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia and the 22q11.2 deletion syndrome, and thus, reveal a distinction between the two…
- Trial name
- FaSchi22 (NCT02634671)
- Testing
- schizophrenia, the 22q11 deletion syndrome, control group
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hôpital le Vinatier
Psychotic Disorders, Anxiety
A Study of Dose-response Relationship and the Evidence Based Multisensory Stimulation Intervention
Design: This parallel randomized controlled trial (RCT) was conducted according to the Consolidated Standards of Reporting Trials (CONSORT).
- Conditions
- Psychotic Disorders, Anxiety, Complementary Therapies, Clinical Trial
- Trial name
- NCT05012709
- Testing
- multisensory stimulation therapy
- Where
- Taiwan
- Volunteers
- 95 people
- Sponsor
- Jianan Psychiatric Center, Ministry of Health and Welfare
Schizophrenia
Study on Predictiors and Mechanism of Conversion to Psychosis in Individuals at Ultra-high Risk Group
Considering the complex pathological mechanism and the poor treatment outcomes of schizophrenia, early detection and intervention gradually become the key work for the foundational and clinical research in schizophrenia.
- Trial name
- NCT03965598
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Xiangya Hospital of Central South University
Schizophrenia
The National Danish Schizophrenia Project
A prospective, longitudinal, multi-centre investigation (16 centres), including 562 patients, consecutively referred during two years, with a first-episode psychosis of ICD-10, F-2 type.
- Trial name
- NCT00221585
- Testing
- Psychosocial treatment/Psychodynamic treatment
- Where
- Denmark
- Sponsor
- University of Copenhagen
Healthy, Healthy Volunteer
Effect of Transcranial Magnetic Stimulation on Memory
This study will examine the effect of transcranial magnetic stimulation (TMS) on short-term memory in healthy adults. Healthy people use their brains to answer short-term memory questions in a different way than do patients with…
- Conditions
- Healthy, Healthy Volunteer, HV
- Trial name
- NCT00105118
- Testing
- Magstim Super Rapid Magnetic Stimulator
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorders
Supervised Treatment of Schizophrenia, a Randomized Controlled Trial.
Patients suffering from Schizophrenia and their families often suffer from poor care because of ignorance about the disorder especially in economically developing countries.
- Trial name
- NCT00392249
- Testing
- Supervised Treatment of Schizophrenia by a family member
- Where
- Pakistan
- Volunteers
- 110 people
- Sponsor
- Lady Reading Hospital, Pakistan
Schizophrenia, Psychotic Disorders
Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention
This is a randomized pilot study of an intervention based on principles of Cognitive Behavioral Therapy (CBT). This intervention is the Health Dialogue Intervention (HDI) and will be compared to a traditional medical model of…
- Trial name
- NCT00980252
- Testing
- Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Illinois Chicago
Psychosis
Neuroplasticity-oriented Cognitive Intervention in Early Onset and First Admission Schizophrenia
The purpose of this study is to reveal the specific effects of computer-aided cognitive training on course and rehabilitation in early onset schizophrenia
- Trial name
- NCT01781364
- Testing
- Brain Fitness Training, Posit Science SF
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Konstanz
Diabetes Mellitus, Type 2, Schizophrenia
Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness
Schizophrenia is associated with a lifespan shortened by 20 years, due to cardiovascular disease (CVD), with antipsychotic (AP) medications understood to contribute to this risk through associated metabolic side-effects.
- Trial name
- NCT02167620
- Testing
- Metformin
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Dissociative Disorders
the Phenotypic and Genetic Profile of Patients With Early Onset Schizophrenia Associated With Autism Spectrum Disorder.
Early onset schizophrenia "early dissociative disorder" is a rare disorder with a low incidence of approximately (1/5000 to 1/20000).
- Trial name
- GenAuDiss (NCT02565524)
- Testing
- genetic and phenotypic profile
- Where
- France
- Volunteers
- 111 people
- Sponsor
- Fondation Lenval
Schizophrenia, Metabolic Syndrome
Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients
The study is performed in 20 different hospitals from 19 cities in China. Three sub-projects are included. About sub-project 1, we build a clinical database system and a biological sample bank for data and samples management…
- Trial name
- NCT03451734
- Testing
- antipsychotic medications, adjunctive group, metformin and lifestyle intervention
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Central South University
Schizophrenia, Schizoaffective Disorder
Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis
This study will assess the effectiveness of an experimental treatment intervention for adolescents and adults who have experienced their first episode of psychosis during the past two years.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder
- Trial name
- NCT01216891
- Testing
- Multi-element, team-oriented treatment
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.